Literature DB >> 7094504

Prediction of steady-state verapamil plasma concentrations in children and adults.

J G Wagner, A P Rocchini, J Vasiliades.   

Abstract

With data on adults from two previous articles it was found that the average steady-state plasma concentration of verapamil in subjects on long-term oral therapy of 80 mg every 6 hr (Y) correlated strongly with the area under the curve from zero to infinity (AUC0-x/6 (X) where the area refers to that for a single oral dose of 80 mg (Y - 2.41X, n - 15, r - 0.923, P less than 0.001). Steady-state concentrations are predictable from the single-dose data, with an average absolute deviation of 11.1%. We gave seven children (7 to 19 yr old) an initial intravenous bolus dose of 0.1 mg/kg, followed by a 20-min constant rate infusion of 0.007 mg/kg/min. Twenty-four hours after the bolus dose they were put on oral therapy (40 to 80 mg every 6 hr) and 1 mo later the minimum steady-state verapamil plasma concentration (Cminss) was measured. Plasma concentration-time data obtained after the infusion were fitted to biexponential (two sets) or triexponential equations (five sets). The coefficients of the postinfusion polyexponential equations were converted to those for the 0.1-mg/kg bolus dose alone. Mean parameters estimated were: plasma clearance 0.500 l/min, steady-state volume of distribution 279 l, V beta 394 l, half-life 9.17 hr, and mean residence time 10.0 hr. Many correlations were made between the oral Cminss values and functions obtained from the intravenous data. The best correlation was that between Cminss and the predicted steady-state concentration at 3 hr after dosing when bolus doses would be given at 6-hr intervals based on the single-dose intravenous date (r = 0.985, P less than 0.001); this correlation allowed Cminss to be predicted with an average absolute deviation of 10%. Norverapamil was measured in plasma after oral dosing, but was not detectable after intravenous dosing.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094504     DOI: 10.1038/clpt.1982.144

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.

Authors:  D O Rumiantsev; V K Piotrovskii; V I Metelitsa; I D Slastnikova; E V Kokurina
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

3.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  The effect of oral verapamil therapy on antipyrine clearance.

Authors:  D O Rumiantsev; V K Piotrovskii; O S Riabokon; I D Slastnikova; E V Kokurina; V I Metelitsa
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of verapamil.

Authors:  S R Hamann; R A Blouin; R G McAllister
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 7.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

8.  Pharmacokinetics of verapamil in patients with hypertension.

Authors:  P Anderson; U Bondesson; U de Faire
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  An investigation of the cause of accumulation of verapamil during regular dosing in patients.

Authors:  J B Schwartz; D R Abernethy; A A Taylor; J R Mitchell
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 10.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.